NEW YORK (360Dx) – Vermillion reported after the close of the market on Thursday that its second quarter revenues were down 21 percent year over year.

For the quarter ended June 30, the company reported total revenues of $708,000, down from $898,000 a year ago. Product revenues were down 27 percent to $627,000 from $860,000 in Q2 2017. The company posted $81,000 in service revenue, up 113 percent from $38,000 in the year-ago quarter.

Vermillion performed 1,884 OVA1 tests in the quarter, down 22 percent from 2,418 OVA1 tests performed in Q2 2017.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.